Domov › Rak dojke › Alabama › Birmingham
Klinične študije za Rak dojke v Birmingham, AL
24 študij za Rak dojke išče udeležence na lokacijah v Birmingham in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Vključevanje udeležencevFaza 2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Vključevanje udeležencevFaza 3
- Central Alabama Research, Birmingham
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Vključevanje udeležencevFaza 2
- Alabama Oncology, Birmingham
PRE-ISPY Phase I/II Oncology Platform Program
Vključevanje udeležencevFaza 1/2
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
Vključevanje udeležencevFaza 2
- University of Alabama at Birmingham, Birmingham
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- University of Alabama At Birmingham Hospital, Birmingham
Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
Vključevanje udeležencev
- The Kirklin Clinic, Birmingham
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of Alabama at Birmingham, Birmingham
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Vključevanje udeležencevFaza 2
- University of Alabama at Birmingham, Birmingham
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Vključevanje udeležencevVabljeni zdravi prostovoljci
- University of Alabama at Birmingham, Birmingham
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Vključevanje udeležencevFaza 1
- University of Alabama Birmingham, Birmingham
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Vključevanje udeležencevOpazovalna študija
- Birmingham Hematology Associates, Birmingham
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Vključevanje udeležencevFaza 2
- University of Alabama, Birmingham
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
Vključevanje udeležencevVabljeni zdravi prostovoljci
- University of Alabama, Birmingham, Birmingham
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Vključevanje udeležencevFaza 1
- Uni of Alabama at Birmingham, Birmingham
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
Vključevanje udeležencev
- The University of Alabama, Birmingham
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Vključevanje udeležencevFaza 2
- University of Alabama at Birmingham, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Vključevanje udeležencev
- University of Alabama at Birmingham, Birmingham
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Vključevanje udeležencevFaza 2
- University of Alabama at Birmingham, Birmingham
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
Vključevanje udeležencevZgodnja faza 1
- The Kirklin Clinic, Birmingham
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Vključevanje udeležencevFaza 2
- University of Alabama Birmingham, Birmingham
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
Vključevanje udeležencev
- The University of Alabama at Birmingham, Birmingham
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
Vključevanje udeležencev
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Birmingham
Študije za Rak dojke v drugih mestih
- New York City, NY136 študij
- Houston, TX126 študij
- Boston, MA112 študij
- Nashville, TN81 študij
- Los Angeles, CA73 študij
- Edison, NJ68 študij
- St. Louis, MO64 študij
- Queens, NY64 študij
- Durham, NC64 študij
- Chicago, IL59 študij
- Philadelphia, PA56 študij
- Dallas, TX55 študij
Druge študije v Birmingham
- Rak (vse vrste)31 študij
- Rak jajčnikov23 študij
- Debelost23 študij
- Nemalicelični pljučni rak22 študij
- Akutna mieločna levkemija21 študij
- Množni mielom18 študij
- BOPC17 študij
- Srčno-žilne bolezni17 študij
- Sladkorna bolezen tipa 216 študij
- Rak endometrija16 študij
- Prekomerna telesna teža16 študij
- Cistična fibroza16 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.